DNA Sequencer for Shared Resource Lab

描述(申请人提供)：这项拨款申请申请资金购买应用生物系统3100遗传分析仪，以取代已有六年历史的应用生物系统377 DNA测序仪，由维克森林大学医学院DNA测序核心实验室(WFUSM)操作。现有的DNA测序仪为超过45笔资助的NIH拨款提供支持。WFUSM教职员工提交的样本中，超过90%是由NIH拨款资助的。DNA测序实验室在方便的校园环境中为研究人员提供低成本、准确的测序技术。作为关键研究工具的自动化DNA测序的需求一直在稳步增长，随着2002年增加多达10个教员职位，预计未来两年对服务的需求将增加约25%。虽然目前的仪器表现良好，但平板凝胶技术正迅速被更灵敏和高效的毛细管电泳所取代。测序技术的主要供应商应用生物系统公司决定停产377 DNA测序仪，这保证了目前使用的377 DNA测序仪将被淘汰。用3100基因分析仪取代377将确保研究人员继续获得最新、最灵敏的测序技术，并使实验室能够向研究人员快速提供测序数据。拟议的仪器将以按服务收费的方式向全体教员提供。该实验室在马克·莱弗利博士的指导和Elyse Jung女士的监督下，已经以这种方式运营了六年。虽然对该仪器的大部分支持将来自用户费用，但维克森林大学医学院的综合癌症中心将提供额外的支持。高质量的仪器、经验丰富的人员和坚实的财政支持相结合，将确保NIH资助的研究人员将从拟议仪器的收购中受益。

DESCRIPTION (provided by applicant): This grant application requests funding for the purchase of an Applied Biosystems 3100 Genetic Analyzer to replace a six year old Applied Biosystems 377 DNA Sequencer that is operated by the DNA Sequencing Core lab of Wake Forest University School of Medicine (WFUSM). The existing DNA sequencer provides support for over 45 funded NIH grants. Over 90% of the samples submitted by WFUSM faculty are funded by NIH grant money. The DNA sequencing laboratory offers low cost, accurate sequencing technology to investigators in a convenient, on-campus setting. The demand for automated DNA sequencing as a critical research tool has grown steadily, and with the addition of up to ten faculty positions in 2002, an increased demand in services of about 25% over the next two years is anticipated. While the current instrumentation has performed well, slab gel technology is rapidly being replaced by more sensitive and efficient capillary electrophoresis. The decision by Applied Biosystems, the major supplier of sequencing technology, to discontinue the 377 DNA sequencer guarantees that the 377 DNA sequencer currently in use will become obsolete. Replacement of the 377 with the 3100 Genetic Analyzer will ensure that researchers have continued access to the most up-to-date, sensitive sequencing technology, and will allow the laboratory to provide rapid delivery of sequencing data to investigators. The proposed instrumentation will be available to the entire faculty on a fee-for-service basis. The lab has been operated in this way for six years, under the direction of Dr. Mark Lively and the supervision of Ms. Elyse Jung. While most of the support for the instrumentation will come from user fees, additional support will be provided by the Comprehensive Cancer Center of Wake Forest University School of Medicine. The combination of high quality instrumentation, experienced personnel, and solid financial support will ensure that NIH-funded researchers will benefit from acquisition of the proposed instrumentation.